Effect of Randomized Lipid Lowering With XXXX and @entity3709 on Cataract Development (from the @entity3413 and @entity3709 in @entity472 Study).

@entity1 @entity3413 @entity231 @entity6 @entity301 @entity3709 @entity617 @entity472 @entity65 @entity165 @entity1851
UNASSIGNED: Recent American College of Cardiology/American Heart Association guidelines on statin initiation on the basis of total @entity65 risk argue that the preventive effect of statins on cardiovascular events outweigh the side effects, although this is controversial. Studies indicate a possible effect of statin therapy on reducing risk of @entity231 . However, the results are conflicting. The @entity3413 and @entity3709 in @entity472 study (NCT00092677) enrolled 1,873 @entity1 with asymptomatic @entity472 and no history of @entity6 , @entity301 , or other serious co-morbidities were randomized (1:1) to double-blind 40  mg @entity3413 plus 10  mg @entity3709 versus placebo. The primary end point in this substudy was incident @entity231 . Univariate and multivariate Cox models were used to analyze: (1) if the active treatment reduced the risk of the primary end point and (2) if time-varying low-density lipoproteins (LDL) @entity165 lowering (annually assessed) was associated with less incident @entity231 per se. During an average follow-up of 4.3  years, 65 @entity1 (3.5%) developed @entity231 . Mean age at baseline was 68  years and 39% were @entity1 . In Cox multivariate analysis adjusted for age, gender, @entity617 treatment, smoking, baseline LDL @entity165 and high sensitivity @entity1851 ; @entity3413 plus @entity3709 versus placebo was associated with 44% lower risk of @entity231 development (hazard ratio 0.56, 95% confidence interval 0.33 to 0.96, p  = 0.034). In a parallel analysis substituting time-varying LDL- @entity165 with randomized treatment, lower intreatment LDL- @entity165 was in itself associated with lower risk of incident @entity231 (hazard ratio 0.78 per 1  mmol/ml lower total @entity165 , 95% confidence interval 0.64 to 0.93, p  = 0.008). In conclusion, randomized treatment with @entity3413 plus @entity3709 was associated with a 44% lower risk of incident @entity231 development. This effect should perhaps be considered in the risk-benefit ratio of statin treatment.
